On December 30, 2022, Beijing CorreGene Biotechnology Co., Ltd (hereinafter referred to as “CorreGene”) and Shenzhen Eureka Biotechnology Co., Ltd. (hereinafter referred to as “EurekaBio”) announced a strategic partnership. Dr. Xie Xingwang, Chairman/CEO of CorreGene, and Mr. Ma Mo, CEO of EurekaBio, acted as representatives of their respective sides and signed the strategic cooperation agreement.
TCR cell therapy, as a revolutionary cancer treatment, has been the focus of extensive research, with significant advancements being made in recent years. However, the development of cell therapy also encounters challenges, such as complex manufacturing processes and limited accessibility. As a leading force in the field of TCR cell therapy, CorreGene has established a systematic TCR research and development platform. Through this platform, the company has successfully overcome various technical challenges associated with TCR cloning and optimization. It enables efficient and high-throughput innovation of TCR drugs. Notably, CorreGene’s proprietary SMART-TCR affinity optimization platform has significantly improved the success rate and efficiency of TCR affinity optimization. This breakthrough has effectively dismantled barriers in TCR drug development, allowing for the development of therapeutic TCR products for cellular immunotherapy of solid tumors. Meanwhile, EurekaBio is committed to the research and innovation of critical technologies and processes in the CGT domain. Through unwavering efforts to drive tangible advancements in its area of expertise, EurekaBio aims to assist customers in producing cell therapy products with greater economic efficiency.
This strategic partnership will capitalize on CorreGene’s research and commercialization capabilities in pioneering cellular immunotherapy while leveraging EurekaBio’s cutting-edge CellSep® series fully closed, automated cell processing systems and the EuLV® lentiviral vector production system based on stable producer cell lines. By combining their technological expertise, service strengths, and shared resources, the collaboration aims to collectively address the challenges in the CGT industry. The overarching goal is to propel the advancement of advanced cellular therapeutic technologies and processes, expedite the commercialization and application of ground-breaking innovations in the CGT field, and serve as a catalyst for the innovative and forward-looking evolution of the CGT industry.
Dr. Xie Xingwang, Chairman of CorreGene, expressed his sincere appreciation to EurekaBio for their immense support throughout the development journey of CorreGene. He expressed his excitement about taking their partnership to new heights. The development of the CGT industry heavily relies on the collective efforts of market players throughout the industry value chain. EurekaBio is devoted to upstream research and innovative breakthroughs in critical technologies and processes within the CGT domain. Conversely, CorreGene is committed to pioneering the development of TCR-based innovative drugs. Through our extensive collaboration, we will leverage the complementarity of resources to enhance production efficiency, develop cutting-edge processes, and reduce production costs in the CGT sector. Ultimately, this synergy will enable cell therapy drugs to significantly benefit patients and improve product accessibility.
Mr. Ma Mo, CEO of EurekaBio, expressed his utmost honor in establishing a strategic collaboration with CorreGene. He said, “CorreGene holds a pivotal position as our esteemed partner, as we share a common vision of addressing industry challenges through self-driven innovation. EurekaBio, positioned as an upstream supplier in the CGT domain, focuses on overcoming foundational challenges such as cell preparation equipment and the stable, scale-up production of lentiviral vectors. By seamlessly collaborating across the industry value chain, we empower our clients to advance research and manufacture more accessible cell therapy products for patients. We believe that our partnership with CorreGene not only brings reciprocal advantages but also sets a remarkable benchmark for fostering pioneering advancements within the CGT industry”
CorreGene, founded by a team of Peking University alumni and returned overseas scholars, is dedicated to the development of innovative therapeutics based on T-cell receptors (TCRs). CorreGene has established a systematic research and development platform for TCR technologies, successfully addressing various technical challenges in TCR cloning and optimization. This platform facilitates efficient and high-throughput innovation of TCR drugs. Leveraging its proprietary SMART-TCR affinity optimization platform, CorreGene has achieved remarkable improvements in the success rate and efficiency of TCR affinity optimization, while also creating a robust framework for the development of soluble TCR protein drugs. Building upon their innovative research capabilities and supported by well-established process development and analytical quality control platforms, CorreGene is actively developing a diverse product pipeline that targets various solid tumors and viral infections. Looking ahead, CorreGene aims to establish itself as a prominent player in the field of TCR immunotherapy. The company will prioritize the development of TCR-T cell therapies and TCR protein drugs for multiple indications, with a focus on treating tumors and chronic infections. By targeting the trillion-dollar disease market, CorreGene seeks to make a significant impact in the field of healthcare.
EurekaBio is an upstream core vendor in the field of CGT. We specialize in researching and developing core technologies and processes, aiming to reduce costs and improve efficiency. As a leading domestic enterprise in cell preparation automation equipment, EurekaBio has independently developed and launched the CellSep®series cell processing systems, along with equipment such as sterile tube welders, heat sealers, and CytoLinX WB single-use rocking bioreactors, providing comprehensive solutions for the production of cell therapy products. Meanwhile, EurekaBio has innovatively developed the EuLV®system. This globally leading technology, based on stable cell producer lines, facilitates large-scale production of lentiviral vectors. By overcoming the technical bottleneck of scale-up production, the EuLV® has significantly enhanced production efficiency and product consistency of lentiviral vectors, while also driving substantial reductions in production costs.
.jpg)
